Prostate tumors develop resistance to androgen deprivation therapy (ADT) by multiple mechanisms, one of which is to express constitutively active androgen receptor (AR) splice variants lacking the ligand-binding domain. AR splice variant 7 (AR-V7, also termed AR3) is the most abundantly expressed variant that drives prostate tumor progression under ADT conditions. However, the molecular mechanism by which AR-V7 is generated remains unclear. In this manuscript, we demonstrated that RNA splicing of AR-V7 in response to ADT was closely associated with AR gene transcription initiation and elongation rates. Enhanced AR gene transcription by ADT provides a prerequisite condition that further increases the interactions between AR pre-mRNA and splicing factors. Under ADT conditions, recruitment of several RNA splicing factors to the 3 0 splicing site for AR-V7 was increased. We identified two RNA splicing enhancers and their binding proteins (U2AF65 and ASF/SF2) that had critical roles in splicing AR pre-mRNA into AR-V7. These data indicate that ADT-induced AR gene transcription rate and splicing factor recruitment to AR pre-mRNA contribute to the enhanced AR-V7 levels in prostate cancer cells.
INTRODUCTION
The primary treatment for metastatic prostate cancer (PCa) is androgen deprivation therapy (ADT). Although initially effective, most tumors progress to castration-resistant PCa (CRPC) even under treatment with the most potent anti-androgens (for example, MDV3100 (enzalutamide) and abiraterone). No curative therapy is available. 1 It is commonly agreed that reactivation of the androgen receptor (AR) signaling contributes to CRPC 2, 3 through several proposed mechanisms, including AR gene amplification/mutation and AR protein overexpression, 4, 5 intratumoral androgen synthesis, 6, 7 aberrant expression of AR co-regulators 8 and alternative AR activation by cytokines and growth factors in the absence of androgens. 9 In addition, recent findings indicate that the AR is also expressed as C-terminaltruncated variants, called ARvs, through alternative RNA splicing. [10] [11] [12] [13] [14] [15] Lacking the ligand-binding domain of full-length AR (AR), ARvs are constitutively active in driving AR-regulated transcription and promoting tumor progression, even under castrate conditions. 11, 13, 15, 16 ARvs regulate a mitotic form of the AR transcriptome rather than one associated with more differentiating functions. 17, 18 Expression of ARvs occurs frequently in CRPC tumors. 19 Although a number of ARvs have been described in PCa cell lines and xenografts, AR splice variant 7 (AR-V7, also termed AR3) is the most commonly expressed ARv in human tissues. 11, 13, 20 Its levels are correlated with increased risk of biochemical relapse 11, 13 and shorter survival time of CRPC patients. 20 These results suggest a critical role of AR-V7 in supporting CRPC. However, the molecular mechanism by which AR-V7 mRNA is spliced remains unclear.
Pre-mRNA splicing involves stepwise assembly of RNA splicing factors to the regions containing 5 0 and 3 0 splicing sites, excision of the intron sequences and re-ligation of the adjacent exons. 21 Alternative RNA splicing is the process whereby exons are selectively excised from the pre-mRNA, resulting in a different combination of exons in the final translated mRNA. 22 AR-V7 mRNA is spliced at the alternative 3 0 splice site (3 0 ss) next to a cryptic exon, exon 3B, rather than the 3 0 ss next to exon 4, resulting in translation of a C-terminal-truncated form of the AR protein. 11, 13 The decision as to which splicing site is excised is determined by both the regulatory RNA sequences (cis elements) and their associated RNA splicing proteins (trans elements). Depending upon the functional significance and location, some regulatory cis elements are termed exonic splicing enhancers (ESE) or intronic splicing enhancers (ISE). 23, 24 In addition, RNA splicing is closely coupled with gene transcription. 25 Both transcription initiation 26 and elongation rates 27, 28 have a significant impact on the outcome of splicing. This is achieved by the association of RNA splicing factors to the transcription machinery when transcription is initiated. [29] [30] [31] These protein complexes move along the gene during transcription elongation, when transcribed pre-mRNA is screened by the RNA spliceosome to define and excise the splice sites, before transcription is terminated. [32] [33] [34] Therefore, the abundance of a specific splice variant is controlled by both gene transcription rate and splicing factor recruitment to the pre-mRNA during the alternative splicing process.
The question that remains to be answered is whether ADT regulates the RNA splicing program that favors RNA synthesis of ARvs as a survival strategy for PCa in response to ADT. In this manuscript, we studied the molecular mechanisms by which AR-V7 was alternatively spliced in response to ADT.
RESULTS
AR and AR-V7 mRNA levels are increased in response to androgen deprivation We first profiled AR and AR-V7 RNA levels in a panel of PCa cell lines: VCaP, LNCaP, LN(AI) and LN95. Both LN(AI) and LN95 cells are derived from LNCaP cells, but have been cultured under longterm ADT conditions, thus possessing an ADT-resistant phenotype. Using an absolute quantification method, real-time quantitative PCR (qPCR) showed that VCaP cells expressed AR RNA that was 5-10 fold higher than LNCaP and LNCaP-derived cells (Figure 1 and Supplementary Figure 1A) , which was consistent with the report that VCaP cells have an increased AR gene copy number. 35 AR RNA level was B17.9-fold higher than AR-V7 in VCaP cells. LNCaP cells expressed extremely low levels of AR-V7 RNA. Both LN(AI) and LN95 cells expressed higher levels of AR-V7 than LNCaP cells. AR-V7 RNA levels in LN95 cells were 30-40% lower than that in VCaP cells. Western blotting assays showed consistently that VCaP cells expressed higher AR protein levels than other cell lines ( Figure 1b and Supplementary Figure 1B) , possibly due to the increase in AR gene copy number in VCaP cells. Both VCaP and LN95 cells expressed comparable levels of AR-V7 protein. LN(AI) cells expressed lower levels of AR-V7 protein, whereas parental LNCaP cells had undetectable levels of AR-V7 protein.
ADT conditions were reported to increase both RNA and protein levels of AR in PCa cell lines and xenografts. 17, 36 To determine whether ADT also regulated AR-V7 expression, we treated PCa cells with dihydrotestosterone (DHT) and/or MDV3100 (Figure 1c ).
DHT reduced AR RNA levels significantly in VCaP and LNCaP cells, but only to a minor extent in LN(AI) cells. AR-V7 levels in LN(AI) cells were also repressed by DHT, following the changes of AR levels. In contrast, neither AR nor AR-V7 RNA levels were altered by DHT or MDV treatment in LN95 cells.
We found that AR-V7 expression was also reversibly regulated by DHT and MDV treatments. After VCaP cells were pre-treated with DHT for 24 h, adding MDV to the culture medium dramatically upregulated AR-V7 RNA and protein levels (Figure 2a-c) . Vice versa, DHT significantly supressed AR-V7 expression after VCaP cells were pre-treated with MDV. Changes in AR-V7 RNA levels were correlated with AR levels. Using primary cultures from MDV-resistant VCaP tumor xenografts grown in mice (n ¼ 10), we further showed that both AR and AR-V7 RNA levels were maintained in relative high levels under maximum ADT conditions, but significantly decreased when DHT was added ( Figure 2d ). As the doubling time of VCaP cells is 53 h, changes in AR and AR-V7 RNA levels cannot be accounted by clonal selection. These results indicated that RNA splicing of AR-V7 was a dynamic and reversible process, which was regulated by AR signaling.
AR-V7 expression is important for VCaP cell proliferation under ADT conditions The functional significance of AR-V7 expression was further tested in VCaP cells by comparing cell proliferation rates under conditions of AR versus AR-V7 knockdown by small interfering RNA (siRNA). siRNA to exon 7 knocked down AR, siRNA to exon 3B knocked down AR-V7 and siRNA to exon 1 knocked down total AR (AR-V7 þ AR). In the presence of androgen depletion and/or MDV treatments, AR-V7 or total AR, but not AR knockdown, significantly reduced VCaP cell growth (Figure 3a) . However, cell growth relied Figure 1 . AR and AR-V7 RNA levels in PCa cells. (a) Total RNA was extracted from VCaP, LNCaP, LN(AI) and LN95 cells. AR and AR-V7 mRNA copy numbers within 20 ng RNA were determined by real-time qPCR using absolute quantification as described in Materials and methods. (b) AR and AR-V7 protein levels were detected by western blotting assays using AR(N-20) and AR-V7 antibodies. (c) VCaP, LNCaP, LN(AI) and LN95 cells were maintained in RPMI1640 medium containing 5% FBS or 5% CSS for 48 h. Cells were treated with vehicle (Veh), 10 nM DHT and/or 5 mM MDV3100 for 24 h. Relative RNA levels of AR and AR-V7 were determined by real-time qPCR using relative quantification to GAPDH. Results were obtained from three independent experiments with samples in triplicates and shown as mean±s.e.m. One-way ANOVA followed by Student's t-test was carried out using GraphPad Prism showing significance with Po0.05 as * or Po0.01 as ** or Po0.001 as ***. Primer sequences and standard curves for measuring RNA levels of AR and AR-V7 were presented in Supplementary Materials and figures.
on AR when DHT was present. Consistent with cell proliferation assays, expression levels of prostate specific antigen (PSA) and transmembrane protease serine2 (TMPSS2) were further dramatically decreased by siRNAs targeting AR-V7 or total AR, when compared with siRNA targeting AR alone under androgen depletion and/or MDV treatment conditions (Figure 3b ). In the presence of DHT, siRNA knocking down AR-V7 did not inhibit PSA and TMPSS2 expression. However, siRNA targeting total AR presented more potent suppressive effects to these genes when compared with siRNA targeting AR only. Interestingly, UGT2B17 and UBE2C were previously demonstrated to be AR-V7-regulated genes in PCa. 19 We further confirmed that AR-V7 was required for UGT2B17 transcription in VCaP cells under ADT conditions. In contrast, DHT-activated AR suppressed UGT2B17 RNA levels, which effects were blocked by AR knockdown. Similar observation was also from UBE2C expression that was inhibited by AR but enhanced by AR-V7 (Supplementary Figure 2) . These findings indicate that under ADT conditions, AR-V7 can replace AR to sustain cell growth and regulate a gene set distinct from AR. Our results support a critical role of AR-V7 that is responsible for PCa phenotype shift from androgen sensitive to CRPC under castration stress. The efficiencies of siRNA knockdown of AR and or AR-V7 were shown by western blotting in Figure 3c . Together, our results indicate that AR-V7 maintains VCaP PCa cell proliferation by an AR signaling mechanism under ADT conditions. AR-V7 RNA splicing is coupled with AR gene transcription As the RNA splicing process was known to be coupled with gene transcription, and our data also indicated that AR-V7 RNA levels were correlated with AR RNA levels, we examined whether active AR-V7 splicing was controlled by the AR gene transcription rate. We applied three different approaches to inhibit AR gene transcription by treating cells with actinomycin D (ActD), benzimidazole (DRB) or trichostatin A (TSA). Cells were also cotreated with either 10 nM DHT or 5 mM MDV for 0, 1, 2, 4, 8 and 16 h (Figure 4 ). In the presence of vehicle, MDV maintained whereas DHT dramatically decreased both AR and AR-V7 RNA levels during 16 h of treatment in VCaP cells, while AR and AR-V7 RNA levels in LN95 cells were maintained at relatively constant levels. However, in both VCaP and LN95 cells, ActD and DRB eliminated, whereas TSA significantly reduced AR-V7 RNA levels correlating with changes of AR RNA levels. ActD forms complexes with doublestranded DNA to prevent RNA pol II from forming the transcription initiation complex, whereas DRB is an inhibitor of C-terminal domain of pol II that inhibits gene transcription at the elongation step. TSA was confirmed to inhibit AR gene transcription in several different PCa cell lines. 37, 38 These results together indicated that AR-V7 splicing was dependent upon AR gene transcription initiation and elongation rates.
Recruitment, but not expression of RNA splicing factors, contributes to AR-V7 splicing Although RNA splicing is coupled with transcription, generation of a RNA splice variant requires splicing factors that recognize and excise the alternative splice sites. We chose a panel of splicing factors including U1A, U2AF65, AFS/SF2, hnRNP I, PSF and p54nrb that were demonstrated to have essential roles in RNA splicing, 39 and measured their protein levels under DHT or MDV treatment. No changes in protein levels of these splicing factors were observed under different treatments and among different cell lines (Supplementary Figure 3) .
We next determined whether recruitment of splicing factors to the AR gene was altered following ADT conditions. Chromatin immunoprecipitation (ChIP) assays were performed with primers amplifying the P1-P3 regions, corresponding to the 5 0 and 3 0 splice regions for AR and AR-V7 ( Figure 5 ). The P4 region is located upstream of the 5 0 UTR (untranslated region) of human GAPDH gene, a region of the gene where there are no active RNA splicing events. It therefore serves as a negative control. Consistent with ADT-induced AR gene transcription, the recruitment of pol II to P1, P2 and P3 regions were significantly higher in MDV-treated VCaP cells. These changes were concurrent with increased recruitments of several RNA splicing factors (U1A, U2AF, ASF/SF2 and p54nrb) to P1, P2 and P3 regions. Exceptions were PSF (no change) and hnRNP I (decreased recruitment). These data suggested that MDV treatment increased spliceosome recruitment to the AR gene to process both AR and AR-V7 RNA splicing. In contrast, although MDV also enhanced pol II and U1A, U2AF and p54nrb onto P1 and P3 regions in LNCaP cells, their recruitments to the P2 region (containing AR-V7 3 0 ss) were not increased by MDV. These observations were consistent with low expression of AR-V7 in LNCaP cells. Together, these results suggested that spliceosome recruitment to the AR gene, rather than alterations in protein levels of splicing factors, contributed to AR-V7 splicing.
Construction of AR-V7 minigene to identify RNA splicing enhancers In order to identify any cis and trans element responsible for AR-V7 splicing, we constructed the AR-V7 minigene plasmid (Figure 6a) , with exon 3B and its flanking B400-bp nucleotide sequence inserted in between exon 3 and exon 4 of the human AR gene. When transiently transfected, the minigene expressed 12-25 fold of AR and 8-300 fold of AR-V7 higher than the levels of endogenous AR transcripts in PCa cell lines (Figure 6b ). Driven by the constitutively active CMV promoter, the levels of minigene transcribed AR-V7 were not affected by DHT or MDV treatment. These observations indicated that gene transcription rate, but not ADT condition per se, directly regulated AR-V7 RNA splicing.
To locate potential RNA sequences responsible for AR-V7 splicing, we screened exon 3B and its flanking region using the Splicing Rainbow 40 and ESEfinder 3.0 41 programs, two bioinformatic tools to predict potential splicing factor binding sites. One ISE and one ESE near the 3 0 ss of exon 3B were identified. The ISE was predicted to bind hnRNP I or U2AF65, whereas the ESE was a potential ASF/SF2 binding site. We applied mutagenesis and cloning techniques to further construct AR-V7 minigenes carrying point mutations at either ISE or ESE site (Figure 6c ). When these mutant AR-V7 minigenes were introduced into PCa cells, only AR-V7 transcript levels, but not AR, were dramatically decreased (Figure 6d ). To further confirm whether the functions of ISE and ESE were mediated through the predicted RNA splicing factors, we transfected AR-V7 minigenes into LNCaP cells in the presence of siRNAs against hnRNP I, U2AF65 and ASF/SF2. The levels of AR CSS for 48 h. Cells were treated with either 10 nM DHT or 5 mM MDV3100 for another 24 h. ChIP assays were performed using antibodies against pol II, U1A, U2AF65, ASF/SF2, p54nrb, PSF, hnRNP I and control IgG. Eluted DNA fragments were used as templates for real-time qPCR. Signals were calculated as percentage of input and blotted as fold changes over control IgG. ChIP data were derived from five independent experiments with triplicate samples per experiment. Student's t-test showed statistical significance with Po0.05 as *, Po0.01 as ** and Po0.001 as ***. Results were obtained from three independent experiments and shown as mean±s.e.m. One-way ANOVA followed by Student's t-test was carried out using GraphPad Prism showing statistical significance with Po0.001 as ***.
transcribed by AR-V7 minigenes were unchanged, regardless of siRNA knockdown or mutations at ESE or ISE within the minigenes (Figure 6e ). In contrast, levels of AR-V7 transcribed by the AR-V7(WT) minigene were dramatically decreased with hnRNP I, U2AF65 or ASF/SF2 knockdown. The AR-V7(ISEm) minigene expressed very low levels of AR-V7, which were insensitive to any knockdown of splicing factors. Interestingly, RNA interference (RNAi) of U2AF65 and hnRNP I, but not ASF/SF2, further decreased AR-V7 levels transcribed by the AR-V7(ESEm) minigene. These findings indicated that both the ISE and the ESE were specifically important for AR-V7 splicing through interactions with U2AF65, hnRNP I and ASF/SF2.
Identification of RNA splicing factors responsible for AR-V7 splicing To further study binding proteins for the ISE and the ESE, we synthesized two 40-bp RNA oligos to perform RNA pull-down assays (Figure 7a ). Oligo 1 contains the ISE, whereas oligo 2 contains the ESE. Their sequences are listed in Supplementary Materials. Both oligos were incubated with purified Flag-tagged U2AF65, hnRNP I and ASF/SF2. hnRNP I and U2AF65 bound oligo 1. These interactions were abolished when the ISE was replaced with the ISEm (Figure 7b) . Interestingly, hnRNP I and U2AF65 can also be pulled down by oligo 2. However, those interactions were not affected by ESE point mutations. ASF/SF2 had a strong association with oligo 2 but not with oligo 1. This interaction was also dramatically decreased when ESE was replaced with the ESEm. In order to show specific U2AF65/hnRNP I-ISE and ASF/SF2-ESE interactions, we also used oligos 1 and 2 to pull down two other RNA splicing factors, U1A and Tra2b. U1A bound both oligos 1 and 2 even in the presence of ISEm and ESEm, whereas Tra2b had no association to either RNA oligo. These results indicate that ASF/SF2 specifically binds the ESE, whereas hnRNP I and U2AF65 bind oligo 1 at the specific ISE site. They also bind oligo 2 but possibly through sequences other than the ESE.
RNA co-immunoprecipitation assays were further performed (Figure 7c ). Antibodies against ASF/SF2, U2AF65 and hnRNP I, but not control immunoglobulin G (IgG), precipitated AR pre-mRNA at Oligo-associated splicing factors were detected by western blotting assays. (c) VCaP cell lysates were immunoprecipitated with antibodies against ASF/SF2, U2AF65 and hnRNP I. Protein associated pre-mRNA were extracted and reverse transcribed and analyzed by regular PCR with primers amplifying P1-3 regions. (d) VCaP cells were treated with either 10 nM DHT or 5 mM MDV3100 for 2 h. RNA immunoprecipitation assays were performed. Real-time qPCR quantified the enrichments of ASF/SF2, U2AF65 and hnRNP I on pre-mRNA at P1-3 regions. Signals were calculated as percentage of input and blotted as fold changes over control IgG. (e) VCaP cells were transfected with siRNAs against control, ASF/SF2, U2AF65 and hnRNP I for 48 h, after which cells were treated with either 10 nM DHT or 5 mM MDV3100 for another 24 h. AR and AR-V7 RNA splicing products were measured by real-time qPCR using relative quantification against GAPDH. A primer set covering GAPDH exon 7 and exon 8 was used as a negative control to monitor GAPDH gene splicing in response to RNAi of ASF/SF2, U2AF65 and hnRNP I. (f and g) AR protein and mRNA were also detected by western and northern blotting assays. Densitometry analyses calibrate RNA and protein bands of the AR gene by 18S and actin as the loading controls. In Figure 7g , both low and high exposures of western blot with AR(N-20) antibody were shown. (h) LN95 cells were transfected with siRNAs against controls ASF/SF2, U2AF65 and hnRNP I for 48 h. AR, AR-V7 and GAPDH splicing products were measured by real-time qPCR. Data were derived from three independent experiments and presented as mean±s.e.m. One-way ANOVA followed by Student's t-test was carried out using GraphPad Prism showing statistical significance with Po0.01 as ** and Po0.001 as ***. the P2 region (containing both the ISE and the ESE). Interestingly, hnRNP I was absent in the P1 region (5 0 ss for both AR and AR-V7) and ASF/SF2 showed an extremely low level at the P3 region (3 0 ss for AR). These observations suggest that hnRNP I functions primarily at the 3 0 ss, whereas ASF/SF2 has a relatively higher specificity to the 3 0 ss for AR-V7, emphasizing its important role for AR-V7 splicing. We further used real-time qPCR to quantify the recruitments of ASF/SF2, U2AF65 and hnRNP I to the AR pre-mRNA at the AR-V7 3 0 ss under DHT or MDV treatment for 2 h in VCaP cells (Figure 7d ). MDV dramatically induced U2AF65 binding, but had no impact on ASF/SF2 and hnRNP I to the P1 region. However, all of these splicing factors had enhanced recruitment to the P2 region by MDV, whereas only U2AF65 and hnRNP I increased associations with the P3 region in response to MDV treatment. These results suggested that ASF/SF2-ESE and U2AF65/hnRNP I-ISE interactions were regulated by ADT condition in contributing to AR-V7 splicing.
To further confirm the functional significance of ASF/SF2, U2AF65 and hnRNP I for AR-V7 splicing, we knocked down each splicing factor in VCaP and LN95 cells, and measured AR and AR-V7 levels by real-time PCR amplifying exon 3/4 and exon 3/3B (Figures 7e and h ). RNA silencing of ASF/SF2, U2AF65 and hnRNP I significantly reduced AR-V7 RNA levels. In addition, hnRNP I knockdown also mildly reduced AR levels. To exclude the possibility that ASF/SF2 and U2AF65 silencing also affect other splicing events particularly that within the AR gene, we further showed that U2AF65 and ASF/SF2 knockdown did not affect AR levels by both northern and western blotting (Figures 7f and g ). In addition, we also designed a pair of primers crossing exons 7/8 of the GAPDH gene to measure its RNA splicing as a control, and showed that RNA splicing of the GAPDH gene was not affected by RNA silencing of ASF/SF2 and U2AF65. The efficiency of RNA silencing was shown by western blotting (Supplementary Figure 4) . These results suggested that both ASF/SF2 and U2AF65, when compared with hnRNP I, were specifically important for AR-V7 splicing.
DISCUSSION
Although extensive studies show that constitutively transcriptional function of ARv is important for CRPC progression, the molecular mechanisms by which ARv is alternatively spliced remain unclear. Our studies demonstrate that AR gene transcription rates and splicing factor recruitment to AR pre-mRNA near the AR-V7 3 0 ss are two important factors contributing to AR-V7 splicing. The ADT condition does not directly regulate levels of AR-V7 splicing. Rather it enhances AR gene transcription rates and contributes indirectly to the generation of AR-V7 splice variant.
Our lines of evidence demonstrated that AR-V7 RNA synthesis depended upon active AR gene transcription. In various experimental conditions, changes in AR-V7 RNA levels were consistent with alterations of AR RNA levels in PCa cells. ADT induced the recruitment of RNA pol II to the AR gene, reflecting active AR gene transcription (Figure 4) . Concurrently, higher AR and AR-V7 levels were observed under ADT conditions. Although ActD, DRB and TSA acted through different mechanisms to decrease AR gene transcription, they showed consistent repressive effects on AR-V7 RNA splicing (Figure 3 ). In addition, turning on or off of AR gene transcription by DHT and MDV reversibly controlled AR-V7 splicing (Figures 1 and 2) . Previous publications showed that AR-V7 RNA was commonly expressed in PCa cells and even normal prostate epithelium cells, 13, 15 and that the ratio of ARv:AR fluctuated between the 0.1-2.5% range depending upon active AR gene transcription by castration or DHT treatment. 36 These results together confirmed that AR-V7 RNA splicing process was coupled with AR gene transcription rate.
Although AR gene transcription provides a favorable genetic environment for AR-V7 RNA splicing, the enzymatic reaction to excise the 3 0 ss for AR-V7 splicing requires recruitment of RNA splicing factor to AR pre-mRNA for AR-V7 RNA synthesis. We showed that interactions of U2AF65-ISE and ASF/SF2-ESE were critical for this splicing event. Mutations at the ISE and the ESE abolished AR-V7 splicing, whereas RNA silencing of U2AF65 and ASF/SF2 decreased AR-V7 levels in both VCaP and LN95 cells. These results suggested that U2AF65 and ASF/SF2, by recognizing the ISE and the ESE, acted as the pioneer factors to direct further recruitment of RNA spliceosome to the AR-V7 3 0 ss. Although U2AF65 and ASF/SF2 might participate in other RNA splicing events, such as splicing the 3 0 ss next to exon 4 for AR, RNA silencing of U2AF65 and ASF/SF2 did not affect AR RNA levels nor did they affect the GAPDH (exon7/8) RNA splicing. Disruption of U2AF65-ISE or ASF/SF2-ESE interactions had no impact on AR RNA levels (Figure 5d ). It is likely that the recruitment of U2AF65 and ASF/SF2 to the AR-V7 3 0 ss is more efficient because of the presence of the ESE and the ISE near the AR-V7 3 0 ss. ASF/SF2 is a concentration-dependent regulator for alternative RNA splicing. Although ADT does not alter its expression level, more AR premRNA is available as a substrate for ASF/SF2 to catalyze RNA splicing reactions. The existence of ESE within the exon 3B therefore is more attractive for ASF/SF2 to be recruited to the AR-V7 3 0 ss and synthesize AR-V7 mRNA. In addition, the involvement of U2AF65 and ASF/SF2 in excising 3 0 ss next to exon 4 might be compensated by other splicing factors. As excision of the AR-V7 3 0 ss is more sensitive to U2AF65 and ASF/SF2 protein levels, they may serve as rate-limiting factors in controlling AR-V7 splicing efficiency. In contrast, although hnRNP I also binds the ISE, knocking down hnRNP I reduces both AR and AR-V7 levels, indicating hnRNP I serves as a general factor regulating both AR and AR-V7 splicing. Together, these results support that AR-V7 splicing is not generated by a random splicing error. Rather, it is executed by specific RNA splicing factors through recognizing specific RNA sequences near AR-V7 3 0 ss. This RNA splicing event is enhanced in response to ADT as AR transcription rates increase.
Our studies also demonstrated that neither AR gene amplification nor rearrangement were required for AR-V7 RNA splicing. Although VCaP cells have amplification of the AR gene, no such genetic aberrance is reported in LN95 cells. However, LN95 cells express comparable AR-V7 RNA levels. Regardless of AR gene amplification, suppression of the AR gene transcription rate or RNA silencing of splicing factors reduced AR-V7 splicing in both LN95 and VCaP cells. In VCaP, LNCaP and LN(AI) cells, AR-V7 RNA levels were repressed by DHT treatment (Figure 1) . Particularly, AR-V7 RNA levels in VCaP cells can be reversibly regulated by DHT or MDV treatment within 24 h (Figure 2 ). These results indicate that AR gene amplification does not attribute to AR-V7 splicing. Rather, AR gene amplification magnifies the levels of all transcripts by the AR gene, supporting VCaP cells as an ideal model to study alternative RNA splicing events of the AR gene. Interestingly, both castration-resistant LN(AI) and LN95 cells express high levels of AR-V7 than their parent LNCaP cells, supporting the hypothesis that generation of AR-V7 contributes to CRPC progression.
An intragenic AR gene rearrangement was reported contributing to AR-V7 RNA synthesis in 22Rv1 cells. 42 No such gene rearrangement was noted in VCaP or castration-resistant LN(AI) and LN95 cells. 35 It could be possible that similar genomic disruption may exist in some other PCa cells. However, AR-V7 mRNA synthesis still requires the removal of intron sequences through the RNA splicing process. RNA splicing factors still need to recognize and excise the 3 0 ss, and ligate the exon 3 with exon 3B. This enzymatic reaction will depend on active AR gene transcription to create a permissible environment and recruitment of splicing factors to AR pre-mRNA. Our data showed that changes in recruitment of U2AF65 and ASF/SF2 occurred within 2 h of MDV treatment (Figure 6d ). Enhanced AR-V7 RNA levels by MDV can be lowered within hours by subsequent DHT treatment (Figures 2a  and b) , indicating that AR-V7 RNA splicing is a dynamic and reversible process.
In summary, our data provide new insights to the complexity of AR gene splicing during CRPC progression of PCa. It invites further investigation that may lead to therapeutic revenues to block AR-V7 expression in CRPC tumors and resensitize current anti-AR therapy.
MATERIALS AND METHODS

Cell culture
The human PCa cell line VCaP (CRL-2876) was purchased from ATCC (Manassas, VA, USA) and LNCaP, C4-2B, LN(AI) and 293T cell lines were generously provided by Drs Gleave, Rennie and Buttyan from the Vancouver Prostate Centre. LN95 cells were described previously and were a generous gift from Dr Alan Meeker of Johns Hopkins University. 18 VCaP and 293T cells were cultured in DMEM, whereas LNCaP and C4-2B cells were cultured in RPMI1640 medium. LN(AI) and LN95 cells were maintained in RPMI1640 medium with charcoal-stripped serum (CSS). CSS was used for steroid studies (Hyclone, Logan, UT, USA). DHT, ActD, DRB and TSA were purchased from Cedarlane (Burlington, ON, Canada). MDV3100 was from Haoyuan Chemexpress (Shanghai, China). Plasmids encoding Flag-tagged RNA splicing factor are U2AF65 (Dr James Manley, Columbia University), ASF/SF2 (Dr Gourisankar Ghosh, UC San Diego), hnRNP I (Dr Allain Fré dé ric, Institute for Molecular Biology and Biophysics Eidgenö ssiche Technische Hochshule, Switzerland) and Tra2b (Dr Stefan Stamm, University of Kentucky).
Reverse-transcriptase PCR and real-time qPCR
Total RNA was extracted using TRIZOL reagent (Invitrogen, Burlington, ON, Canada) and treated with deoxyribonuclease at room temperature for 15 min to eliminate any DNA contamination. The reverse transcription reaction was performed using random hexamers and superscript II (Invitrogen), after which the product was used as a template for PCR. Real-time qPCR was performed on the ABI PRISM 7900 HT system (Applied Biosystems, Burlington, ON, Canada) using the FastStart Universal SYBR Green Master mix (Roche, Laval, QU, Canada) as we previously reported. 43 Cycling was performed using default conditions of the 7900HT Software (Applied Biosystems)-2 min at 50 1C and 10 min at 95 1C-followed by 40 cycles of 15 s at 95 1C and 1 min at 60 1C. Absolute quantification followed the previous report, 44 AR and AR-V7 cDNAs were quantified by NanoDrop (Thermo Scientific, Wilmington, DE, USA), and their copy numbers were calculated by copy number (molecules/ml) ¼ concentration(g/ml)/(bp size of double-stranded product Â 660) Â 6.022 Â 10
23
. A series of dilutions of the cDNAs were used as templates for real-time qPCR as standards for AR or AR-V7. A standard curve was drawn by plotting the C T value against the log of the copy number of molecules. The specific AR and AR-V7 copy numbers were calculated by the equation drawn from the graph. The relative quantification method has been described before using GAPDH or 18s rRNA as the internal control genes. 43 All real-time qPCR assays were carried out using three technical replications, as well as three independent cDNA syntheses. Primer information is listed in the Supplementary Materials.
Western blot and ChIP
After treatments, cells were incubated with lysis buffer (50 mM Tris pH8.0, 150 mM NaCl, 1% NP40, 0.5% sodium deoxycholate and 0.1% SDS) followed by a brief sonication to extract protein lysate. Lysates were immunoblotted with specific antibodies (detailed in Supplementary Materials). ChIP assays followed the protocol that we previously reported. 43, 45 DNA templates retrieved from ChIP were analyzed by real-time qPCR on the ABI PRISM 7900 HT system (Applied Biosystems) using the FastStart Universal SYBR Green Master (Roche). Enrichments of immunoprecipitated DNA fragments were determined by the threshold cycle (Ct) value. Data were calculated as a percentage of input and plotted as fold changes over control IgG. ChIP data were derived from five independent experiments with samples in triplicate. Data are presented as mean ± s.e.m.
MDV-resistant VCaP xenografts
MDV-resistant xenografts of VCaP cells were generated by injecting VCaP cells subcutaneously in castrate SCID (severe combined immunodeficiency) mice (2 Â 10 6 cells mixed 1:1 with Matrigel). When xenograft tumors reached 500-800 mm 3 , the animals were euthanized, tumors were removed, collagenase were digested and again injected subcutaneously into castrate SCID mice 1:1 with Matrigel. Mice were treated with MDV3100 (10 mgm/kg) per gavage 5 days a week. When xenografts reached 800-1000 mm 3 , mice were euthanized, tumors were final minced and 1/3 of each minced tumor was grown in a 100-mm plastic culture dish with RPMI1640 plus 5% CSS and 5 mM gentamicin. Cells were treated with 10 mM MDV3100, 1 nM DHT or MDV3100 plus DHT for 24 h. Total RNA was collected to measure AR and AR-V7 RNA levels by real-time qPCR. All animal studies were approved by the University of Washington Institutional Animal Care and Use Committee (IACUC). 
AR-V7 minigene construction
The human genomic BAC clone (RP11-75E16) was provided by The Centre for Applied Genomics, The Hospital for Sick Children, University of Toronto. It was used as the template for PCR to amplify exon 3, exon 3B and exon 4, and their flanking intron regions (B300-400 base pairs) by Platinum Taq DNA Polymerase High Fidelity (Invitrogen). Three DNA fragments were cloned into the plasmid vector pCMV2 (Sigma, Oakville, Ontario, Canada) between the EcoRI and SalI sites. Full sequences of the vectors will be provided upon request. DNA sequencing confirmed the integrity of the final AR-V7 construct. DNA mutagenesis was further performed using the AR-V7 minigene as the template to construct AR-V7 (ESEm) and AR-V7 (ISEm).
RNA protein interaction assay RNA oligo pull down was performed by first immobilizing 0.4 nmol biotinlabeled RNA oligonucleotides (Invitrogen) onto 100 ml of streptavidin beads (Pierce, Rockford, IL, USA) in a final volume of 500 ml of binding buffer (20 mM HEPES-KOH, pH 7.9, 80 mM potassium glutamate, 0.1 mM EDTA, 1 mM DTT and 20% glycerol) at 4 1C for 2 h. RNA splicing factors, U2AF65, ASF/SF2, hnRNP I, U1A and Tra2b proteins, were purified by transfecting plasmids encoding Flag-tagged splicing factors into 293T cells, followed with purification using Anti-Flag M2 Affinity gel (Sigma) as reported. 45 The immobilized RNA oligos were then incubated with 50 mgpurified splicing factors in binding buffer containing 30 U/ml RNase OUT and 15 mg/ml yeast tRNA in a final volume of 400 ml at 4 1C for 2 h. The beads were washed three times with binding buffer and once with washing buffer (20 mM HEPES-KOH, pH 7.9, 0.1 mM EDTA, 1 mM DTT, 75 mM KCl and 20% glycerol), and suspended in 40 ml of 2 Â sodium dodecyl sulfate sample buffer and boiled for 5 min. Eluted proteins were analyzed by western blot. RNA oligo sequences are listed in Supplementary Materials.
RNA co-immunoprecipitation
RNA co-immunoprecipitations were performed as previously reported 46, 47 with the following modifications. Cell nuclei were first extracted by isotonic buffer (10 mM Tris/HCl, pH 7.4, 10 mM NaCl, 2.5 mM MgCl 2 , 1mM DTT, protease inhibitor cocktail, 30 U/ml RNase OUT, 10 mM b-glycerophosphate and 0.5 mM NaVO 4 ). After incubation on ice for 7 min, nuclei were collected by centrifugation at 700 g for 7 min, re-suspended in isotonic buffer supplemented with 90 mM of NaCl and 0.5% Triton X-100, and briefly sonicated. Soluble nuclear extracts were first precleared with protein A/GSepharose beads (Santa Cruz, Dallas, TX, USA) and control IgGs, then immunoprecipitated with 2 mg of ASF/SF2, hnRNP I or U2AF65 antibody. After extensive washes by isotonic buffer, the precipitated antibodyantigen complexes were first incubated with DNase I (RNase free, Ambion, Burlington, ON, Canada) for 15 min at 37 1C, followed with 50 mg of proteinase K (Roche) treatment for 15 min at 37 1C. Co-precipitated RNA was then extracted by TRIzol and used for cDNA synthesis and PCR analyses. Enrichment of precipitated RNA was determined by the Ct value. Data were calculated as percentage of input and plotted as fold changes over control IgG. RNA co-immunoprecipitation data were derived from three independent experiments with samples in triplicate. Results were presented as mean ± s.e.m.
Northern blotting
VCaP cells were transfected with control siRNA or siRNA against U2AF65, ASF/SF2 and hnRNP I for 48 h. Total RNA was extracted by using Trizol (Invitrogen). Twenty microgram of total RNA were used for northern blotting analysis to detect AR and 18S RNA levels as described. 48 
Statistics
Data were presented as mean ± s.e.m. that were calculated from three or more different experiments. Statistical significances were calculated by using one-way analysis of variance (ANOVA) and paired Student's t-test. A P-value of o0.05 was considered significant. *represents Po0.05, **represents Po0.01 and ***represents Po0.001.
